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ABSTRACT 
Objective: Counterfeit medicines represent a major health risk in the treatment of various pathologies. They are responsible for resistance 
emergence in the treatment of infectious diseases. This study was conducted in order to identify illegal and legal drugs marketed in the city of 
Lubumbashi and assess the quality of all samples concerned by this study. 
Methods: The study included albendazole and metronidazole for oral administration. Visual inspection of medicines, investigation of the 
authenticity of drugs from pharmaceutical regulatory authorities, and determination of content were used as study parameters. 
Results: A total of 34 samples were collected including 19 of albendazole and 15 of metronidazole. 11 (32%) samples were not permitted to be 
marketed. 9 (26 %) samples were substandard according to the US Pharmacopoeia in terms of the content of active ingredient: all of them, the 
active ingredient was found to present in a lower amount (under-dosing). The proportion of non-compliance is highest among medicines not 
permitted to be marketed (78% vs 8.0%; p˂0.005
Conclusion: 
).  
It is obvious that strengthening the capacity of drug regulatory authority of the DR Congo can reduce the influx of 
counterfeit/substandard drugs in Lubumbashi. 
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Counterfeit drugs represent a huge threat to public health because 
of the high risk of damage they can cause to patients who consume 
them [1-3]. It is estimated that over 10% of drugs in circulation in 
the world are counterfeit, but the rate is much higher in 
developing countries because of the weakness and lack of drug 
regulatory systems [4-8]. Indeed, pharmaceutical regulatory 
authority is a structure which is responsible for the coordination 
and monitoring the pharmaceutical sector, in order to preserve 
public health, its deficiency, weakness or ineffectiveness promotes 
the importation, manufacturing and distribution of drugs without 
supervision. This causes proliferation of fakes in chain distribution 
national [9, 10]. 
Counterfeiting affects all types of medicine, however, the medicines 
concerned are not the same across countries. In industrialized 
countries, the targets tend to be lifestyle medicines such as narcotics 
or treatments for erectile dysfunction [1, 11]. Poor countries are 
mainly affected by counterfeit anti-infective [1, 11, 12].  
It has been reported that in developing countries, counterfeit 
medicines often involves essential drugs used in life-threatening 
diseases such as antiparasitics. Albendazole and metronidazole are 
among the most antiparasitics used in DR Congo (Democratic 
Republic of Congo) [11, 13, 14]. Albendazole is a broad-spectrum 
anthelmintic; it is used for the treatment of Threadworm, hookworm 
and Tapeworm [15]. Metronidazole is very effective in the treatment 
of amoebiasis, trichomoniasis, giardiasis and many other parasitic 
diseases [16]. The high demand for these medicines makes them a 
very attractive target for counterfeiters who benefit from the large 
amount of products that they easily sell in a short period of time. 
Considering all questions above-mentioned, it seemed important to 
conduct a preliminary study on counterfeiting of albendazole and 
metronidazole with the objective to identify illegal and legal drugs 
marketed in the city of Lubumbashi and assess the quality of all 
samples concerned by this study.  
MATERIALS AND METHODS 
Geographically this study included drugs obtained in Lubumbashi, 
the provincial capital of Haut-Katanga, south-eastern province of DR 
of Congo, the city has seven townships: Lubumbashi, Kampemba, 
Kamalondo, Kenya, Katuba, Ruashi and Annex. The samples were 
collected in four types of pharmaceutical establishment: 
establishment of wholesale, pharmacies opened to public, hospital 
pharmacies and public market.  
Samples were purchased from 15
Sampling method 
th December 2014 to 10thJanuary 
2015. The selection of collecting site was not the same for the types 
of pharmaceutical structures indicated above. Thus, the 
establishment of wholesale are twenty-two in Lubumbashi, they are 
all located in Lubumbashi city center and have been all selected as 
the collecting site of our samples. Regarding hospital pharmacies, 
general reference hospitals are eleven (Katuba, Kamalondo, Kenya, 
Kisanga, Kampemba, Jason Sendwe, Ruashi, Vangu, Munua, 
Tshiamilemba and Kowe), they were automatically chosen for the 
collection site of our samples. Concerning pharmacies opened to the 
public, their selection was made randomly, we randomly selected 5 
pharmacies in each township of the city of Lubumbashi. Public 
markets where medicines are sold are six in Lubumbashi: Kenya, 
Zambia, M'zee, Texaco, Congo and Katuba, we selected all those 
markets to collect our samples.  
Each sample was collected with his withdrawal slip which contains the 
necessary information on the traceability of samples collected: active 
ingredient and strength, brand name, manufacturing and expiring 
date, batch number, registration number, quantity purchased, date and 
place of collection and the price of each sample acquired. 
Samples which were collected from the same or different 
pharmaceutical establishment and carrying a label indicating the 
same mentions: active ingredient, brand name, name and address of 
the manufacturer or marketer, the number of marketing 
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authorization, batch number, date of manufacture and expiry, batch 
number, and having the same pharmaceutical form and strength 
were considered as one sample. For the purpose of authenticity 
investigation, the medicines were required to be sold with their 
outer containers (boxes or plastic bags), or at least with their 
blisters, providing minimum information about the manufacturer or 
marketer and the batch/lot number.  
Pharmaceutical forms that were involved in this study are those 
for oral administration, i.e. tablets, capsules, and oral 
suspensions. All the samples were kept at room temperature 
until analysis.  
The standards (table 1) used in this study have been ordered and 
obtained from approved 
 
suppliers. 
Table 1: standard products 
Product 
information 
Batch n ° Supplier Reference 
Albendazole 2.0 European pharmacopeia  A0325100 
Metronidazole 2.1 European pharmacopeia M1850000 
 
Observational analysis 
Identification of a potentially counterfeit medicine passes first 
through careful visual inspection of the product. It consisted in 
examining: the location of mentions on the packaging, the physical 
aspect of pharmaceutical forms, the bar code, hologram, logo, 
typography, drawings or pictures, spelling words, language (s) 
mentioned (s) by the manufacturer, the instructions, the color of the 
packaging and product etc. [15, 17]. 
Each sample received a visual inspection questionnaire which 
incorporated information on samples collected including primary 
and secondary packaging, the physical appearance of the tablet, 
capsule, solution for oral drop and powder for suspension, the 
particle size powders for drinkable suspensions forms.  
Investigation of authenticity 
Besides complete analytical tests, WHO advises contacting the 
manufacturer on the label and the pharmaceutical regulatory 
authorities (PRA) of the country of marketing and manufacturing 
[15, 17]. In this study, we went to meet the pharmaceutical 
regulatory authority of D R Congo. The purpose of this 
investigation was to verify whether medicines collected in the 
pharmaceutical market were registered and authorized to be 
marketed in DR Congo. Thus, a formulary was intended for the 
local pharmaceutical regulatory authority who has the official list 
of medicines registered and authorized to be marketed in D R 
Chemical analysis 
Congo. 




A Genesys 10S UV-VIS spectrophotometer was used for 
measurement of the absorbance of solutions.  
Albendazole [18] 
Preparation standard 
In a volumetric flask of 50 ml, weigh exactly 25 mg of albendazole, 
dissolved in methanol-glacial acetic acid to get a concentration of 
500 µg/ml. Prepare (table 2) six different concentrations. 
  
Table 2: Dilutions of standard of albendazole 
Prepared solution Dilution ratio Concentration(µg/ml) Absorbance 
solution 1 0.5 ml/100 ml 2.5 0.963 
solution 2 0.5 ml/50 ml 5 1.986 
solution 3 0.75 ml/50 ml 7.5 2.942 
solution 4 0.5 ml/25 ml 10 4.028 
solution 5 0.5 ml/20 ml 12.5 4.948 
solution 6 1.5 ml/50 ml 15 5.875 
 
The absorbance (fig. 1) was measured at 235 nm against the blank and we regenerated a regression line.  
 
Fig. 1: Calibration curve of albendazole 
 
Metronidazole 
In a volumetric flask of 100 ml, weigh exactly 10 mg of 
metronidazole, dissolved in methanol to get a concentration of 100 
µg/ml. Prepare (table 3) six different concentrations.  
[14] 







Solution 1 4 ml/100 ml 4 0.1 
Solution 2 6 ml/100 ml 6 0.139 
Solution 3 8 ml/100 ml 8 0.177 
Solution 4 10 ml/100 ml 10 0.216 
Solution 5 12 ml/100 ml 12 0.252 
 
The absorbance (fig. 2) was measured at 235 nm against the blank 
and we regenerated a regression line. 
Preparation samples 
Samples of albendazole and metronidazole were dissolved and 
diluted to reach a concentration of 10µg/ml.
Statistical analysis 
  
Data analysis was performed using Epi-info version 7.0 
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 2: Calibration curve of metronidazole 
RESULTS AND DISCUSSION 
Sampling 
34 samples were collected from 21 pharmaceuticals establishments: 
19 of albendazole and 15 of metronidazole. establishments of 
wholesale provided about 42% of samples, followed by pharmacies 
opened to public pharmacies (27%), and respectively 15% and 17% 
for hospital pharmacies and public market. The predominance of 
samples provided by establishments of wholesale can be explained 
by the fact that they supply the majority of other pharmaceutical 
establishments: pharmacies opened to public, hospital pharmacies 
and the drugs sold in public markets. The most represented 
pharmaceutical form is a tablet with 50% and respectively 44% and 
6% for oral suspension and capsule form. All samples collected had 
an identifiable country of origin: 44% of samples collected were 
manufactured in India, 18 % were from France, 12% for Pakistan 
and DR Congo, others countries do not exceed 10% (fig. 3)
 
. The price 
of purchased samples fluctuates between 0.08 USD and 5.6 USD for 
albendazole, and from 0.11 USD to 5.3 USD for metronidazole.  
 
Fig. 3: Distribution of samples collected 
 
according to origin 
country 
Authenticity 
Investigation of samples authenticity revealed that 11 (32%) 
samples were not authorized to be marketed in the Democratic 
Republic of Congo. 6 (55%) cases concerned albendazole, and 5 
(45%) for metronidazole. Samples illegally traded in DR Congo are 
mostly from Asia (fig.4) 91%: 55% for Pakistan and 36% for India, 
France represents 9%. 
The investigation method of drugs authenticity has been practiced 
rarely and often incomplete, because of the time and budget 
required for its efficient working. This is the case of Khail et al. 
(2013) [19] who investigated the authenticity of drugs from the 
medical regulatory authority of manufacturers country and 
manufacturer, 
 
only 3 of 11 medical regulatory authority replied to 
requests for verification of the legitimacy of manufacturers and 
samples. Six of 15 manufacturers participated to the study. 
 
Fig. 4: Distribution of samples illegally marketed in the DR 
Congo 
 
according to origin country 
Visual inspection 
Of 34 samples collected, 6 (18%) samples were suspected to be 
counterfeit. We give illustrations of two samples (fig. 5 and 6). 
Indeed, the medicine suspected to be counterfeited (Ib) reproduce 
on its primary and secondary packaging information in English and 
Arabic. This is shown that these products were normally intended 
exclusively for Arab or English countries. The brand name and the 
logo of sample Ia are reproduced exactly. The investigation of drug 
authenticity to pharmaceutical regulatory authority revealed that 
the authorization and registration of the product Zentel were 
obtained for France as a country, and there is no Zentel registered in 
DR Congo which is from Pakistan as it’s the case of sample Ib. The 
two samples were collected in two different establishments of 
wholesale and the price of the sample Ia is more expensive than 
sample Ib: 0.11 USD for medicine manufactured in Pakistan (sample 
Ib) and 4.88 USD for a sample from France (Sample Ia). This 
corroborates the theory that stipulates that drug prices could serve 
as a predictor factor to detect counterfeiting in comparisons 




Fig. 5: Medicine legally marketed in DR CONGO (Ia) 
 
Content analysis 
The percentage content of the samples (table 4) was obtained 
through calculations using the linear equation obtained from the 
regression analysis of albendazole and metronidazole. 
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Fig. 6: Medicine illegally marketed in DR CONGO (Ib) 
 
Of 34 samples collected in this study, 9 (26%) were found to be non-
compliant in terms of dosage of active ingredient as specified in the 
US Pharmacopeia (90%-110%) [21, 22]. The active ingredient was 
found to present in a lower amount (under-dosing) for all samples 
non-complaints. Albendazole is the most represented with 5 samples 
(56%) non-compliant, followed by metronidazole with 4 (44%) 
samples. The tablet form represents 56 % of non-compliance 
followed by oral suspension form with 44%. These findings differ 
from that found by Aka et al. (2005) in Cote d’Ivoire, who had found 
that of 15 samples albendazole, one sample presented an anomaly, 
this non-compliance was due to a total absence of active ingredient. 
Musa et al. (2011) found that out of 15 samples of metronidazole 
collected in Nigeria; only one had presented an anomaly of active 
ingredient content.  
Non-compliant samples detected are all from different types of 
collection site: the establishment of wholesalers are the most 
represented with 44% of non-compliance, followed by markets 
publics (33%) and successively 22% and 11% for pharmacies open 
to public and hospital pharmacies. This shows that substandard 
medicines problem affects the entire pharmaceutical market in 
Lubumbashi. Elsewhere, 44% of non-compliance was from Pakistan, 
followed by India with 33% and respectively 11% for France and DR 
Congo. 
Out of 9 Samples non-compliant, samples illegally marketed in DR 
Congo represent around 78% (7 samples) of non-compliance. All of 
them were the case of under-dosing. Among the active ingredient 
concerned by these non-compliances, albendazole is the most 
concerned with 57% of non-compliance (table 5). It has been 
reported that counterfeit drugs are rarely effective and even 
dangerous and harmful to human health [2, 17, 23]. On the other 
hand, Aka et al. (2005) found that from 44 samples collected in Cote 
d’Ivoire, 42 were not registered, the determination of content active 
ingredient revealed that only one sample was not compliant 
(absence of active ingredient), this sample was not registered in Côte 
d’Ivoire.
 
Table 4: Result of determination active ingredient content 
N ° Sample Strenght Content obtained (90-110%) Conclusion 
1 Alb1 Susp 40 mg/ml 94 Complaint 
2 Alb2 Susp 40 mg/ml 108 Complaint 
3 Alb3 Susp 40 mg/ml 99 Complaint 
4 Alb4 Susp 40 mg/ml 58 Non Complaint 
5 Alb5 Susp 40 mg/ml 96 Complaint 
6 Alb6 Susp 40 mg/ml 107 Complaint 
7 Alb7 Susp 40 mg/ml 102 Complaint 
8 Alb8 Susp 40 mg/ml 100 Complaint 
9 Alb 9 Susp 40 mg/ml 84 Non Complaint 
10 Alb 10  400 mg 95 Complaint 
11 Alb 11  400 mg 103 Complaint 
12 Alb 12  400 mg 89 Non Complaint 
13 Alb 13  400 mg 103 Complaint 
14 Alb 14  400 mg 67 Non Complaint 
15 Alb 15  400 mg 107 Complaint 
16 Alb 16  400 mg 93 Complaint 
17 Alb 17  400 mg 96 Complaint 
18 Alb 18  400 mg 51 Non Complaint 
19 Alb 19  400 mg 92 Complaint 
20 Met 1 500 mg 104 complaint 
21 Met 2 500 mg 98 complaint 
22 Met 3 500 mg 103 complaint 
23 Met 4 250 mg 91 complaint 
24 Met 5 500 mg 52 non complaint 
25 Met 6 500 mg 70 non complaint 
26 Met 7 500 mg 106 complaint 
27 Met 8 250 mg 99  complaint 
28 Met 9 500 mg 100 complaint 
29 Met 10 40 mg/ml 31 non complaint 
30 Met 11 40 mg/ml 39 non complaint 
31 Met 12 25 mg/ml 99 complaint 
32 Met 13 25 mg/ml 94 complaint 
33 Met 14 25 mg/ml 91 complaint 
34 Met 15 25 mg/ml 104 complaint 
 
Legend: Alb: albendazole; Met: metronidazole 
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Table 5: Results of non-compliant samples illegally marketed in DR Congo 
N ° Sample Strength Content obtained (%) Conclusion 
1 Alb4 40 mg/ml 58 Non Complaint 
2 Alb 9 40 mg/ml 84 Non Complaint 
3 Alb 12  400 mg 89 Non Complaint 
4 Alb 14 400 mg 67 Non Complaint 
5 Met 5 500 mg 52 non complaint 
6 Met 10 40 mg/ml 31 non complaint 
7 Met 11 40 mg/ml 39 non complaint 
From the above, comparing non-complaints between medicines registered and not registered in DR Congo, we found in this study that the 
proportion (table 6) of non-compliance is the highest among the samples not permitted
 
 to be marketed (78% vs 8% %; p˂0.005). 
Table 6: Conformity of active ingredient content of samples according to their authenticity 
 Medicines complaints Medicines non-compliant Total 
Medicines illegally marketed 2 7 9 
Medicines legally marketed 23 2 25 
 
Study limits  
Though the purchase of sample was done with discretion so as not to 
attract the attention of people around, in public markets, the sale of 
drugs is an activity that is not officially recognized by the authorities, 
some sellers mobile or fixed have been reluctant to us, that situation 
did not allow us to obtain some desired samples. It is true that the 
sample size cannot be generalized to overall pharmaceutical market 
in Lubumbashi but it reflects the situation of the pharmaceutical 
market in Lubumbashi and for the first time this study gave 
interesting information on the quality of legally and illegally 
medicines marketed in Lubumbashi. 
CONCLUSION 
This study was undertaken with the aim of detecting drugs illegally 
and legally marketed in the DR Congo and to assess the quality of all 
medicines collected. The study showed that drugs marketed illegally 
in DR Congo represent a potential risk in the treatment of infectious 
diseases because 78% of non-compliance found in this study 
concerned medicine illegally marketed in DR Congo. 
It is obvious that strengthening the capacity of the pharmaceutical 
regulatory authority of DR Congo will reduce the influx of 
counterfeit drug and substandard. It is also essential that a 
strengthened control at the borders to be permanent in order to 
reduce the presence of substandard/counterfeit drugs in the 
pharmaceutical market Congolese.  
In the future a further study and extended will allow: (a) to 
determine the prevalence of counterfeit active ingredients 
concerned by this study (b) to widen the sample size (c) to add other 
tests laboratory (galenic tests) to assess the impact of the active 
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